508 related articles for article (PubMed ID: 36322089)
1. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
Ge F; Huo Z; Cai X; Hu Q; Chen W; Lin G; Zhong R; You Z; Wang R; Lu Y; Wang R; Huang Q; Zhang H; Song A; Li C; Wen Y; Jiang Y; Liang H; He J; Liang W; Liu J
JAMA Netw Open; 2022 Nov; 5(11):e2239778. PubMed ID: 36322089
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
[TBL] [Abstract][Full Text] [Related]
3. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis.
Xu J; Yan C; Li Z; Cao Y; Duan H; Ke S
Ann Surg Oncol; 2023 Mar; 30(3):1597-1613. PubMed ID: 36380254
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis.
Wang J; Zhang K; Liu T; Song Y; Hua P; Chen S; Li J; Liu Y; Zhao Y
Front Oncol; 2022; 12():974684. PubMed ID: 36158679
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.
Tian C; Yu Y; Wang Y; Yang L; Tang Y; Yu C; Feng G; Zheng D; Wang X
Front Immunol; 2024; 15():1352873. PubMed ID: 38440727
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials.
Zhu J; Leng X; Gao B; Wang B; Zhang H; Wu L; Ma J; Tan Y; Peng L; Han Y; Wang Q
Front Immunol; 2022; 13():1041233. PubMed ID: 36591306
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Xu J; Cai Y; Hong Z; Duan H; Ke S
Int J Surg; 2024 Jan; 110(1):490-506. PubMed ID: 37800587
[TBL] [Abstract][Full Text] [Related]
13. Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
Yuan Z; Cui H; Wang S; Liang W; Cao B; Song L; Liu G; Huang J; Chen L; Wei B
Front Oncol; 2023; 13():1103320. PubMed ID: 36776290
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
Wang J; Tong T; Zhang G; Jin C; Guo H; Liu X; Zhang Z; Li J; Zhao Y
Front Immunol; 2024; 15():1339757. PubMed ID: 38352873
[TBL] [Abstract][Full Text] [Related]
15. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Zhang C; Hong HZ; Wu YL; Zhong WZ
JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.
Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Zhao M; Chen S; Li C; Du Y; Li P
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765557
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: a systematic review and meta-analysis.
Han YH; Bo JQ; Liu LX
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7134-7147. PubMed ID: 37606124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
